Genome Publications
https://doi.org/10.61096/978-81-981372-2-7_9

Chapter 9

Hematology and Thrombosis Management

Toncy k Thomas
Associate Professor, Indira Gandhi Institute of Pharmaceutical Sciences,
Perumbavoor, Ernakulam, Kerala, India
Riya Mathew
Associate Professor, Indira Gandhi Institute of Pharmaceutical Sciences,
Perumbavoor, Ernakulam, Kerala, India
Athira J Nair
Associate Professor, Indira Gandhi Institute of Pharmaceutical Sciences,
Perumbavoor, Ernakulam, Kerala, India

Abstract: Hematology encompasses the study of blood and its disorders, while thrombosis represents a major pathological process involving aberrant clot formation within the vasculature, contributing significantly to morbidity and mortality worldwide. The delicate equilibrium between procoagulant and anticoagulant forces underpins the physiological process of hemostasis; disruption of this balance can result in either hemorrhagic or thrombotic complications. With increasing prevalence of thrombotic disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction, there has been substantial evolution in diagnostic modalities and therapeutic strategies. This chapter provides an extensive review of the physiology and pathophysiology of hemostasis and thrombosis, emphasizing clinical entities like venous thromboembolism, disseminated intravascular coagulation, and hematologic malignancies. Core pharmacologic interventions including anticoagulants, antiplatelet agents, fibrinolytics, and gene therapies are examined in the context of recent advances, safety concerns, and individualized patient care. Special considerations in pregnancy, cancer, renal/hepatic dysfunction, and pediatric/geriatric populations are highlighted to promote patient-centered therapy. The role of pharmacogenomics in optimizing anticoagulant efficacy and minimizing toxicity is discussed alongside emerging therapies in hemostasis management. Finally, this chapter presents future perspectives on targeted biologics, RNA therapeutics, gene editing, and digital tools that promise to transform thrombotic disease management in the coming decades.

Keywords: Hemostasis, Thrombosis, Anticoagulants, Coagulopathy, Hematologic Disorders

Citation: Toncy K Thomas, Riya Mathew, Athira J Nair. Hematology and Thrombosis Management. *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems*. 2025; Pp89-98.
https://doi.org/10.61096/978-81-981372-2-7_9

1.0 INTRODUCTION

Hematology is a dynamic field that investigates the physiology, pathophysiology, and treatment of disorders affecting blood and the hematopoietic system. It spans a broad spectrum of diseases, from benign anemias and bleeding disorders to complex malignancies such as leukemia and lymphoma. Among these, thrombotic disorders are particularly notable for their widespread prevalence and devastating clinical consequences. Thrombosis the pathological formation of blood clots within vessels constitutes a critical intersection between hematology, cardiology, and vascular medicine.

Thrombotic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, and myocardial infarction, remain leading causes of death and disability globally. The global incidence of venous thromboembolism (VTE) alone is estimated at 1–2 per 1,000 individuals annually, with a high rate of recurrence and long-term morbidity [1]. Arterial thromboses, on the other hand, are typically associated with atherosclerosis and are driven primarily by platelet aggregation, requiring different therapeutic interventions [2].

The clinical management of thrombosis involves a sophisticated interplay of pharmacologic agents targeting various points in the coagulation cascade, platelet function, and fibrinolytic pathways. Genetic predispositions, comorbid conditions such as malignancy and autoimmune diseases, and lifestyle factors such as immobility and smoking significantly influence thrombosis risk [3]. The physiological equilibrium between thrombosis and hemostasis is delicate, where disturbances can lead to life-threatening hemorrhagic or thrombotic complications. As a result, hematology and thrombosis management require personalized assessment and adherence to evidence-based protocols, utilizing current understanding of pharmacokinetics, predictive biomarkers, and clinical guidelines.

Recent advances in molecular biology and pharmacogenomics have revolutionized our understanding of coagulation and thrombosis. The advent of direct oral anticoagulants (DOACs), reversal agents, and novel antithrombotic compounds has significantly expanded the therapeutic arsenal. Integration of artificial intelligence and predictive analytics is now facilitating risk stratification, individualized treatment, and outcome monitoring, heralding a new era of precision medicine in thrombosis management [4].

2.0 Physiology of Hemostasis and the Coagulation Cascade

Hemostasis is the physiological mechanism that prevents excessive bleeding upon vascular injury. It consists of three tightly regulated and overlapping phases: vasoconstriction, primary hemostasis, and secondary hemostasis. The process concludes with fibrinolysis, ensuring clot dissolution after tissue repair. Primary hemostasis begins with vascular constriction and exposure of subendothelial collagen and von Willebrand factor (vWF), which recruit circulating platelets. These platelets adhere to the vascular injury site and become activated, releasing granules containing ADP, thromboxane A2, and serotonin. These agonists amplify the aggregation response and lead to the formation of a platelet plug [5].

Secondary hemostasis involves the activation of a complex proteolytic cascade known as the coagulation cascade, divided into intrinsic, extrinsic, and common pathways. The extrinsic pathway is triggered by tissue factor exposure and the binding of factor VIIa, while the intrinsic pathway is initiated by contact activation involving factors XII, XI, IX, and VIII. Both converge on the common pathway where activated factor X (Xa), together with factor V, catalyzes the conversion of prothrombin (factor II) into thrombin. Thrombin then cleaves fibrinogen into fibrin monomers, which polymerize to form a stable clot, further reinforced by factor XIIIa-mediated cross-linking [6].

Anticoagulant mechanisms regulate this process and include antithrombin III, protein C and protein S systems, and tissue factor pathway inhibitor (TFPI), all of which limit excessive clot propagation. Fibrinolysis, the final phase, is mediated primarily by plasmin, which degrades fibrin into soluble degradation products. Plasmin is generated from plasminogen by tissue plasminogen activator (tPA) and is tightly regulated by plasminogen activator inhibitor-1 (PAI-1) and α2-antiplasmin [7]. This equilibrium between clot formation and resolution ensures hemostatic integrity without pathologic thrombosis.



Figure 9.1: Coagulation and Platelet Activation

3.0 Pathophysiology of Thrombosis

Thrombosis arises when the physiological balance between procoagulant and anticoagulant forces is disrupted, resulting in pathological clot formation. The classical paradigm explaining thrombogenesis is Virchow's triad, which includes endothelial injury, hypercoagulability, and stasis of blood flow [8]. Endothelial injury, often due to hypertension, hyperlipidemia, smoking, or inflammation, exposes subendothelial matrix proteins and tissue factor, initiating coagulation. Hypercoagulability may result from inherited thrombophilias such as factor V Leiden, prothrombin gene mutations, protein C or S deficiency, and antithrombin III deficiency, or acquired conditions including malignancy, pregnancy, and antiphospholipid syndrome [9].

Venous thrombi primarily consist of fibrin and red blood cells and are typically associated with low-flow states such as prolonged immobilization or venous stasis. Arterial thrombi, in contrast, are rich in platelets and develop under high shear stress, often superimposed on atherosclerotic plaques. Systemic inflammation also contributes to thrombogenesis by enhancing tissue factor expression, impairing fibrinolysis, and inducing endothelial activation. Notably, COVID-19 has been linked to a unique coagulopathy characterized by microvascular thrombosis and elevated D-dimer levels, reinforcing the interaction between inflammation and thrombosis [10].

In summary, the development of thrombotic disease involves a multifaceted interplay of cellular and molecular mechanisms. Recognition of the underlying pathophysiology is crucial for accurate diagnosis, risk stratification, and therapeutic targeting.

4.0 Common Hematologic Disorders Associated with Thrombosis

Several hematologic disorders predispose individuals to thrombosis, either directly or as complications of the primary disease. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the most common manifestations of venous thromboembolism (VTE). DVT typically affects the lower limbs and presents with pain, swelling, erythema, and warmth, whereas PE occurs when a thrombus embolizes to the pulmonary arteries, causing dyspnea, pleuritic chest pain, and in severe cases, hemodynamic instability. The diagnosis of DVT relies on Doppler ultrasonography, while computed tomography pulmonary angiography (CTPA) remains the gold standard for PE [11].

Disseminated intravascular coagulation (DIC) is a complex syndrome characterized by systemic activation of coagulation leading to microvascular thrombosis and secondary consumption of platelets and clotting factors, resulting in bleeding. It is commonly triggered by sepsis, trauma, malignancy, or obstetric complications. Laboratory findings include prolonged prothrombin time (PT), activated partial thromboplastin time (aPTT), elevated D-dimer, and reduced fibrinogen levels [12].

Thrombotic microangiopathies (TMAs), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), present with microangiopathic hemolytic anemia, thrombocytopenia, and end-organ damage. TTP is caused by a deficiency of ADAMTS13, a metalloprotease that cleaves vWF multimers, while typical HUS is usually triggered by Shiga toxin-producing bacteria. Treatment includes plasma exchange and immunosuppressive therapy [13].

Hematologic malignancies, such as lymphoma, multiple myeloma, and acute leukemias, are associated with increased thrombotic risk due to tumor-mediated hypercoagulability, chemotherapy, and central venous catheter use. Prophylactic or therapeutic anticoagulation is often required, particularly during high-risk periods such as induction therapy or hospitalization [14].

5.0 Diagnostic Approaches in Thrombosis and Hematology

The evaluation of thrombotic disorders necessitates a comprehensive diagnostic strategy that integrates clinical presentation with laboratory investigations and imaging modalities. The initial laboratory assessment often includes a complete blood count (CBC) to evaluate platelet levels and identify anemia or leukocytosis that might suggest underlying malignancy or infection. Coagulation studies such as prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and thrombin time (TT) provide insights into both the intrinsic and extrinsic pathways of the coagulation cascade. D-dimer levels, which reflect fibrin degradation, are useful for excluding VTE in low-risk patients but lack specificity in hospitalized or inflammatory states [15].

Imaging plays a pivotal role in confirming thrombotic diagnoses. Duplex ultrasonography is the first-line modality for suspected DVT, providing both anatomic and hemodynamic data. In contrast, computed tomography pulmonary angiography (CTPA) is the gold standard for diagnosing PE due to its high sensitivity and specificity. Magnetic resonance venography or conventional contrast venography may be employed in cases involving atypical sites or inconclusive ultrasound results [16].

Platelet function testing is essential in evaluating bleeding disorders, antiplatelet resistance, or perioperative risks in patients on chronic antiplatelet therapy. Methods such as light transmission aggregometry, platelet function analyzer (PFA-100), and point-of-care devices like Verify Now offer varying degrees of sensitivity and clinical applicability. Genetic testing for thrombophilia is considered in patients with unprovoked thrombosis at a young age, recurrent pregnancy loss, or a strong family history. Common mutations evaluated include factor V Leiden, prothrombin G20210A, and deficiencies of protein C, protein S, and antithrombin III [17].

Risk stratification tools have become integral in clinical decision-making. The Wells score helps estimate pretest probability for DVT or PE and guides the need for further diagnostic imaging. The Pulmonary Embolism Severity Index (PESI) aids in identifying PE patients suitable for outpatient treatment. For anticoagulated individuals, the HAS-BLED score evaluates the risk of major bleeding and informs clinical decisions regarding the intensity and duration of therapy [18].

Collectively, these diagnostic tools and frameworks allow for a systematic and personalized approach to the assessment and management of thrombotic and hematologic disorders.

Table 9.1: Diagnostic Tools in Thrombosis Evaluation

Diagnostic Test/Tool	Purpose	Clinical Relevance
Complete Blood Count (CBC)	Platelet count, anemia, infection indicators	Detects hematologic abnormalities
Prothrombin Time (PT/INR)	Evaluates extrinsic pathway	Monitors warfarin therapy
Activated Partial Thromboplastin Time (aPTT)	Evaluates intrinsic pathway	Monitors unfractionated heparin
D-dimer	Detects fibrin degradation products	Rules out VTE in low-risk patients
Duplex Ultrasonography	Imaging for suspected DVT	First-line imaging modality
Computed Tomography Pulmonary Angiography (CTPA)	Confirms pulmonary embolism	Gold standard for PE diagnosis
Genetic Testing	Detects thrombophilia mutations	Factor V Leiden, prothrombin G20210A
Wells Score	Clinical prediction tool	Estimates pre-test probability for DVT/PE

6.0 Antithrombotic Therapy: Anticoagulants and Antiplatelet Agents

The pharmacologic management of thrombosis centers on agents that inhibit different components of the coagulation system or platelet function. Unfractionated heparin (UFH) exerts its effect by enhancing the activity of antithrombin III, thereby inhibiting thrombin (factor IIa) and factor Xa. It requires intravenous administration and frequent aPTT monitoring due to its variable pharmacokinetics. Low-molecular-weight heparins (LMWHs), such as enoxaparin and dalteparin, offer more predictable dosing and are typically administered subcutaneously. They preferentially inhibit factor Xa and require less frequent monitoring, although anti-Xa assays are used in select populations such as pregnant or obese patients [19].

Vitamin K antagonists (VKAs), primarily warfarin, act by inhibiting the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X. Warfarin therapy necessitates regular INR monitoring and is influenced by dietary vitamin K intake and numerous drug interactions. Despite these challenges, it remains the agent of choice for patients with mechanical heart valves or certain inherited thrombophilias [20].

Direct oral anticoagulants (DOACs) have revolutionized anticoagulation therapy with fixed dosing, rapid onset, and fewer interactions. Dabigatran is a direct thrombin inhibitor, whereas rivaroxaban, apixaban, and edoxaban inhibit factor Xa. These agents are approved for prevention and treatment of VTE, stroke prevention in non-valvular atrial fibrillation, and, in some cases, cancer-associated thrombosis. While routine monitoring is not required, renal function must be assessed regularly due to renal clearance pathways [21].

Antiplatelet agents are critical in the management of arterial thrombosis. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and platelet aggregation. P2Y12 receptor inhibitors such as clopidogrel, prasugrel, and ticagrelor block ADP-mediated platelet activation and are integral to dual antiplatelet therapy (DAPT) in acute coronary syndromes and post-percutaneous coronary intervention. Glycoprotein IIb/IIIa inhibitors like abciximab are used in high-risk PCI but are limited by bleeding risk [22].

The selection and intensity of antithrombotic therapy must consider bleeding risk, drug interactions, renal/hepatic function, and patient adherence. Reversal strategies include protamine sulfate for heparins, vitamin K and prothrombin complex concentrates for warfarin, idarucizumab for dabigatran, and andexanet alfa for factor Xa inhibitors [23].

Table 9.2: Comparison of Anticoagulants

Anticoagulant	Mechanism of Action	Route	Monitoring	Reversal Agent
Unfractionated Heparin	Inhibits thrombin and factor Xa via antithrombin	IV/SubQ	aPTT	Protamine sulfate
Low-Molecular-Weight Heparin	Primarily inhibits factor Xa via antithrombin	SubQ	Anti-Xa in select cases	Protamine sulfate (partial)
Warfarin	Inhibits vitamin K-dependent clotting factors (II, VII, IX, X)	Oral	INR	Vitamin K, PCC
Dabigatran	Direct thrombin inhibitor	Oral	None routinely	Idarucizumab
Rivaroxaban	Direct factor Xa inhibitor	Oral	None routinely	Andexanet alfa
Apixaban	Direct factor Xa inhibitor	Oral	None routinely	Andexanet alfa

7.0 Management Strategies for Specific Thrombotic Conditions

Management strategies vary according to the type, location, and severity of thrombotic events. In cases of acute DVT and PE, immediate anticoagulation with LMWH or DOACs is standard. For hemodynamically unstable PE, systemic thrombolysis or catheter-directed thrombolysis may be warranted. Long-term anticoagulation is generally continued for three to six months, with extended therapy considered in unprovoked or recurrent VTE [24].

In atrial fibrillation, stroke prevention is guided by the CHA_2DS_2-VASc score, with DOACs preferred over warfarin in non-valvular cases. In patients with mechanical valves, warfarin remains the only approved oral anticoagulant. Left atrial appendage occlusion devices are emerging as alternatives in patients with contraindications to long-term anticoagulation [25].

Cancer-associated thrombosis poses unique challenges due to concurrent bleeding risks and dynamic disease courses. LMWH has long been the standard, but DOACs are now supported for select cancer types, particularly those without high bleeding risk (e.g., gastrointestinal malignancies). Treatment duration is usually extended beyond six months in the presence of active malignancy or chemotherapy [26].

Thrombosis associated with COVID-19 represents a recent paradigm shift. Hospitalized patients are routinely given prophylactic LMWH, with therapeutic-intensity anticoagulation considered in non-ICU patients with elevated D-dimer and low bleeding risk. Evidence continues to evolve, emphasizing the need for institutional protocols and individualized assessment [27].

Interventional options such as inferior vena cava filters are reserved for patients with contraindications to anticoagulation, while mechanical thrombectomy may be lifesaving in massive PE or limb-threatening DVT. Each approach requires multidisciplinary coordination, including hematology, cardiology, and interventional radiology input, to optimize outcomes.

8.0 Special Populations and Considerations

The management of thrombotic disorders in special populations presents unique challenges due to physiological variations and comorbidities. In pregnancy, the hypercoagulable state is driven by elevated levels of fibrinogen and clotting factors, along with decreased fibrinolytic activity. Low-molecular-weight heparin (LMWH) is the preferred anticoagulant during pregnancy due to its safety profile and minimal placental transfer, while warfarin is avoided due to teratogenic effects, particularly in the first trimester. Close peripartum monitoring and planning are essential to minimize bleeding risks during labor and delivery [28].

In pediatric patients, thrombosis is relatively uncommon but may occur due to congenital thrombophilias, catheter-associated events, or underlying systemic illness. Dosing of anticoagulants in children is complicated by developmental hemostasis, necessitating age-specific protocols and careful laboratory monitoring. LMWH remains the agent of choice, with emerging data supporting cautious use of DOACs in select adolescents [29].

Geriatric patients present increased risks for both thrombosis and bleeding due to age-related changes in pharmacokinetics, polypharmacy, renal impairment, and frailty. DOACs are generally favored over VKAs in this group because of predictable pharmacodynamics and reduced monitoring requirements. However, close assessment of renal function and fall risk is critical in this population [30].

Patients with renal or hepatic dysfunction require tailored anticoagulation strategies. Renal impairment affects drug clearance, necessitating dose adjustments or selection of agents with hepatic metabolism. Warfarin is often preferred in end-stage renal disease, while DOACs require caution or are contraindicated in advanced renal failure. Liver disease alters synthesis of both procoagulant and anticoagulant proteins, complicating the interpretation of coagulation tests and increasing the risk for both bleeding and thrombosis [31].

In transplant recipients and oncology patients, the risk of thrombosis is elevated due to immunosuppressive therapy, indwelling catheters, and tumor-related factors. Thromboprophylaxis must be balanced against bleeding risk and interactions with chemotherapy. LMWH remains the mainstay in active cancer, though DOACs have emerged as suitable alternatives in select cases [32].

9.0 Monitoring and Reversal of Antithrombotic Therapy

Effective and safe use of antithrombotic agents depends on appropriate monitoring and timely reversal in cases of bleeding or planned procedures. Warfarin therapy requires regular INR checks, with target values typically between 2.0 and 3.0, or higher for patients with mechanical heart valves. Dietary consistency and awareness of interacting drugs are vital for stable INR control [33].

Heparin therapy is monitored via activated partial thromboplastin time (aPTT) for unfractionated heparin, while anti-Xa levels are used to assess LMWH activity in certain populations. Although DOACs do not require routine monitoring, specialized assays such as dilute thrombin time (for dabigatran) and anti-Xa levels (for rivaroxaban or apixaban) may be utilized in overdose, bleeding, or urgent surgical settings [34].

Bleeding management strategies depend on the severity and type of antithrombotic agent used. Minor bleeding may require dose interruption and supportive care, whereas major bleeding mandates prompt discontinuation of therapy and administration of reversal agents. Protamine sulfate reverses the effects of heparin, while vitamin K and prothrombin complex concentrates (PCCs) counteract warfarin-induced anticoagulation. Idarucizumab neutralizes dabigatran, and andexanet alfa is available for factor Xa inhibitors, although cost and availability may limit use [35].

Bridging therapy is essential for patients requiring temporary interruption of anticoagulation, such as during surgery. Warfarin is typically held for five days preoperatively, with LMWH bridging considered for high-risk patients. DOACs are held 24–48 hours before procedures depending on bleeding risk and renal function. Postoperative resumption of anticoagulation should be individualized based on hemostasis and thrombotic risk [36].

10.0 Recent Advances and Future Perspectives

The field of thrombosis management has witnessed rapid evolution with the advent of novel therapeutics and technology. New classes of anticoagulants targeting factor XIa, such as asundexian and milvexian, are under investigation for thromboprophylaxis with a potentially lower bleeding risk. These agents offer promise, particularly for patients requiring long-term therapy where hemorrhagic complications remain a major concern [37].

RNA-based therapeutics represent a novel strategy, with small interfering RNA (siRNA) compounds like fitusiran targeting antithrombin synthesis to rebalance coagulation in hemophilia. Antisense oligonucleotides directed against factor XI are also progressing through clinical trials and may offer additional options for patients with inherited or acquired coagulopathies [38].

Gene therapy has made significant strides in hematology, especially for hemophilia A and B. Adeno-associated virus (AAV) vectors delivering factor VIII or IX genes have demonstrated durable expression for over a year in phase 3 trials. These developments mark a shift from replacement therapy to potentially curative approaches, though challenges such as immunogenicity, vector persistence, and high costs remain [39].

Gene editing technologies, particularly CRISPR-Cas9, are being explored for correction of monogenic disorders like sickle cell disease and beta-thalassemia. While not yet applied widely in thrombotic disorders, the potential to correct inherited thrombophilias through targeted editing remains an exciting avenue for future research [40].

Artificial intelligence and digital health platforms are also being integrated into thrombosis management. Machine learning algorithms can analyze electronic health records to predict thrombotic events and bleeding risks, aiding clinical decision-making. Wearables and mobile apps enhance adherence and real-time monitoring, while clinical decision support tools assist in guideline-based dosing and transitions of care [41].

These innovations underscore the dynamic nature of hematology and thrombosis pharmacology, signaling a future characterized by personalization, automation, and improved patient outcomes.

11.0 CONCLUSION

The comprehensive management of hematologic and thrombotic disorders is central to modern clinical practice, requiring a nuanced understanding of physiology, pharmacology, and patient-specific variables. With thrombosis remaining a leading cause of preventable morbidity and mortality globally, the importance of individualized treatment plans rooted in current evidence cannot be overstated. Advances in anticoagulation therapies, improved diagnostic tools, and the integration of pharmacogenomics have collectively expanded the clinician's ability to tailor therapy while minimizing bleeding risks.

Despite these innovations, challenges persist, particularly in special populations and patients with comorbidities. Effective management hinges not only on drug selection but also on proper monitoring, patient education, and coordinated care. The emergence of gene-based therapeutics, digital health integration, and AI-driven decision support tools heralds a promising future where thrombotic diseases may be predicted, prevented, and treated with unprecedented precision.

Moving forward, continued investment in clinical research, equitable access to cutting-edge therapies, and refinement of clinical guidelines will be essential. As our understanding of the complex interplay between coagulation, immunity, and vascular biology deepens, the potential for curative and preventive strategies will become increasingly tangible, ultimately improving outcomes and quality of life for patients affected by hematologic and thrombotic conditions.

REFERENCES

1. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-74.
2. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227-34.
3. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003;1(7):1343-8.
4. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40.
5. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958-65.
6. Monroe DM, Hoffman M. The clotting system a major player in wound healing. Haemophilia. 2012;18(5):11-6.
7. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129(3): 307-21.
8. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143(2): 180-90.
9. Kujovich JL. Thrombophilia. Hematol Oncol Clin North Am. 2012;26(3):445-66.
10. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743-6.

11. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-52.
12. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33.
13. Scully M, Cataland S, Coppo P, et al. Consensus on diagnosis and management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15(2):323-34.
14. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-7.
15. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism. Ann Intern Med. 2004;140(8):589-602.
16. Qanadli SD, El Hajjam M, Mesurolle B, et al. Pulmonary embolism detection: comparison of spiral CT angiography and ventilation-perfusion scintigraphy. Radiology. 2000;217(2):447-55.
17. Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1-16.
18. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Europace. 2011;13(5):723-46.
19. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants. Chest. 2012;141(2 Suppl): e24S-43S.
20. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: CHEST guideline. Chest. 2012;141(2 Suppl): e152S-84S.
21. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
22. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57.
23. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-20.
24. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran vs. warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52.
25. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS guideline for the management of atrial fibrillation. Circulation. 2019;140(2):e125-e151.
26. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline. J Clin Oncol. 2020;38(5):496-520.
27. ATTACC, ACTIV-4a, and REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med. 2021;385(9):790-802.
28. Bates SM, Rajasekhar A, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: CHEST guideline. Chest. 2016;149(2):315-52.
29. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: CHEST guideline. Chest. 2012;141(2 Suppl):e737S-801S.
30. Proietti M, Lip GYH. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation: balancing risks and benefits. J Am Geriatr Soc. 2019;67(3):481-9.
31. Tripodi A. Hemostasis abnormalities in chronic liver disease: clinical significance and perspectives. Semin Liver Dis. 2019;39(1):001-14.
32. Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310-7.
33. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: CHEST guideline. Chest. 2008;133(6 Suppl):160S-198S.
34. Pernod G, Albaladejo P, Godier A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants. Anaesth Crit Care Pain Med. 2016;35(1):35-49.
35. Siegal DM, Cuker A. Reversal of anticoagulation. Hematology Am Soc Hematol Educ Program. 2015;2015(1):560-7.
36. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: CHEST guideline. Chest. 2012;141(2 Suppl):e326S-50S.

37. Weitz JI, Bauersachs R, Becker B, et al. Factor XIa inhibition with asundexian to prevent stroke in atrial fibrillation. N Engl J Med. 2023;388(14):1305-15.
38. Pasi KJ, Rangarajan S, Mitchell N, et al. Targeting antithrombin in hemophilia A or B with fitusiran: a phase 1 trial. N Engl J Med. 2017;377(9):809-18.
39. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994-2004.
40. Dever DP, Bak RO, Reinisch A, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539(7629):384-9.
41. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-9.